Mesenchymal Cell News Volume 4.50 | Dec 18 2012

Superparamagnetic Iron Oxide Nanoparticle Targeting of MSCs in Vascular Injury
Scientists showed that magnetic targeting of mesenchymal stem cells (MSCs) gives rise to a six-fold increase in cell retention following balloon angioplasty in a rabbit model using a clinically applicable permanent magnet. [Biomaterials] Abstract

Mesenchymal Stem Cell-Based Cell Engineering with Multifunctional Mesoporous Silica Nanoparticles for Tumor Delivery
The authors describe a mesenchymal stem cell-based multifunctional platform to target orthotopic glioblastoma by integrating the tumor targeted delivery of mesenchymal stem cells and the multimodal imaging advantage of mesoporous silica nanoparticles. [Biomaterials] Abstract

Short-Term, Long-Term and Paracrine Effect of Human Umbilical Cord-Derived Stem Cells in Lung Injury Prevention and Repair in Experimental Bronchopulmonary Dysplasia
Researchers observed that human umbilical cord-derived perivascular cells and mesenchymal stem cells exerted short- and long-term therapeutic benefit without adverse lung effects in rat pups exposed to hyperoxia, a well-established bronchopulmonary dysplasia  model, and offer new therapeutic options for lung diseases characterized by alveolar damage. [Thorax] Abstract | Press Release

Control Over the Gradient Differentiation of Rat BMSCs on a PCL Membrane with Surface-Immobilized Alendronate Gradient
A linear density gradient of alendronate, a molecule that is capable of promoting osteogenic differentiation of bone mesenchymal stem cells (BMSCs), was created on the aminolyzed poly(ε-caprolactone) (PCL) membrane. [Biomacromolecules] Abstract

Induction of Mesenchymal Stem Cell Chondrogenesis by Polyacrylate Substrates
The authors investigated whether polyacrylate substrates modeled on the functional group composition and distribution of the RGD integrin-binding site could induce mesenchymal stem cells to undergo chondrogenesis in the absence of exogenous transforming growth factor beta. [Acta Biomater] Abstract

Umbilical Cord Blood-Derived Mesenchymal Stem Cells Inhibit, but Adipose Tissue-Derived Mesenchymal Stem Cells Promote Glioblastoma Multiforme Proliferation
To examine the anticancer therapeutic application of mesenchymal stem cells (MSC) from different sources, researchers established two different kinds of human MSC: umbilical cord blood-derived MSC and adipose tissue-derived MSC. They used these MSC in a co-culture assay with primary glioblastoma multiforme (GBM) cells to analyze how MSC from different sources can inhibit GBM growth. [Stem Cells Dev] Abstract

The Effect of Link N on Differentiation of Human Bone Marrow-Derived Mesenchymal Stem Cells
Scientists aimed to determine how Link N may influence human mesenchymal stem cell (MSC) differentiation, as a prelude to using Link N and MSC supplementation in unison for optimal repair of the degenerated disc. [Arthritis Res Ther] Abstract | Full Article

Selective Development of Myogenic Mesenchymal Cells from Human Embryonic and Induced Pluripotent Stem Cells
The authors aimed to establish a practical differentiation method to induce skeletal myogenesis from both human embryonic stem and induced pluripotent stem cells. To accomplish this goal, they developed a novel stepwise culture method for the selective expansion of mesenchymal cells from cell aggregations called embryoid bodies. [PLoS One] Full Article

Effect of Lumican on the Migration of Human Mesenchymal Stem Cells and Endothelial Progenitor Cells: Involvement of Matrix Metalloproteinase-14
Researchers aimed to analyze the role of lumican in the control of mesenchymal stem cell migration and transition to functional endothelial progenitor cell. [PLoS One] Full Article

REVIEWS

New Facility Will Bridge Research and Stem Cell Therapies
The University of Rochester Medical Center has opened the doors on a new facility that will enable researchers to create, study, and ultimately use stem cells and their offspring in early-phase experimental human therapies. The Upstate Stem Cell cGMP Facility was created with $3.5 million in support from the Empire State Stem Cell Board. [University of Rochester Medical Center] Press Release

National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

NEW The New York Academy of Sciences: Metabolic Determinants of Stem Cell Pluripotency and Cell Fate Commitments
February 1, 2013
New York City, United States

Visit our events page to see a complete list of events in the mesenchymal cell community.

Product Quality Scientist (STEMCELL Technologies, Inc.)

Scientist – Endothelial Cell Research (STEMCELL Technologies, Inc.)

Research Technologist – Cell Separation (STEMCELL Technologies, Inc.)

Scientist or Engineer – hPSC Bioengineer (STEMCELL Technologies, Inc.)

Postdoctoral Position – Tumorigenicity of Mesenchymal Stem Cells Department of Molecular Cell Biology (Weizmann institute of Science)

Postdoctoral Position – Tumor Stem Cells (Cancer Institute of New Jersey)

Postdoctoral Position – Osteogenic Differentiation of Mesenchymal Stem Cells (University of Connecticut Health Center)

Postdoctoral Position – Hematology and Regenerative Medicine (Karolinska Institute)

PhD Student – Stem Cells in Tooth Regeneration (King’s College London)

Postdoctoral Position – Macrophage and Mesenchymal Stem Cell Interactions for Tissue Regeneration (Kent State University)

Recruit Top Talent: Reach more than 55,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Mesenchymal Cell News? Click here to submit!

Comments or Suggestions? Email info@connexoncreative.com with your feedback.